# A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

Source: https://onco.cc/trials/nct07439653/  
OnCo record `nct07439653` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TORL-5-700 in non-Hodgkin lymphoma, run by TORL Biotherapeutics, LLC, now recruiting.

## Summary

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT07439653 by TORL Biotherapeutics, LLC, with 155 participants planned, started 2026-03-31 and due to reach its primary completion in 2029-03-31. Interventions recorded: TORL-5-700, TORL-5-700 at MTD/RP2D and TORL-5-700 at MTD/RP2D in combination with another agent.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07439653
- Phase: 1/2
- Setting: A Phase 1/2, First-in-Human, Open-Label, Multicenter Study of TORL-5-700 as a Monotherapy and in Combination for Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
- Sponsor: TORL Biotherapeutics, LLC
- Enrolled: 155

## Sources

- ClinicalTrials.gov NCT07439653: https://clinicaltrials.gov/study/NCT07439653

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/nct07439653.json